Specificity of antinuclear autoantibodies recognizing the dense fine speckled nuclear pattern: Preferential targeting of DFS70/LEDGFp75 over its interacting partner MeCP2

Clinical Immunology

Volumn 161, Issue 2, 2015, Pages 241-250

  Basu, Anamika ^a   Woods Burnham, Leanne ^a   Ortiz, Greisha ^a   Rios Colon, Leslimar ^a   Figueroa, Johnny ^a   Albesa, Roger ^b   Andrade, Luis E ^c   Mahler, Michael ^b   Casiano, Carlos A ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INOVA DIAGNOSTICS INC   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Autoantibodies; Autoimmunity; Dense fine speckles; DFS70; LEDGFp75; MeCP2

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIGEN; DENSE FINE SPECKLED NUCLEAR PROTEIN 70; LENS EPITHELIUM DERIVED GROWTH FACTOR; LENS EPITHELIUM DERIVED GROWTH FACTOR P75; METHYL CPG BINDING PROTEIN 2; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; PROTEIN BINDING; PSIP1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RHEUMATIC DISEASE; BLOOD; CONFOCAL MICROSCOPY; GENETICS; IMMUNOBLOTTING; IMMUNOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBODIES, ANTINUCLEAR; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; HUMANS; IMMUNOBLOTTING; METHYL-CPG-BINDING PROTEIN 2; MICROSCOPY, CONFOCAL; PROTEIN BINDING; RNA INTERFERENCE; TRANSCRIPTION FACTORS;

EID: 84942693635     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.07.014     Document Type: Article

References (61)

1. Tan E.M. Autoantibodies and autoimmunity: a three-decade perspective. A tribute to Henry G. Kunkel. Ann. N. Y. Acad. Sci. 1997, 815:1-14.
2. Mahler M., Pierangeli S., Meroni P.L., Fritzler M.J. Autoantibodies in systemic autoimmune disorders. J. Immunol. Res. 2014, 2014:263091.
3. Agmon-Levin N., Damoiseaux J., Kallenberg C., Sack U., Witte T., Herold M., et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann. Rheum. Dis. 2014, 73:17-23.
4. Dellavance A., Viana V.S., Leon E.P., Bonfa E.S., Andrade L.E., Leser P.G. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J. Rheumatol. 2005, 32:2144-2149.
5. Mahler M., Fritzler M.J. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin. Dev. Immunol. 2012, 2012:494356.
6. Mahler M., Hanly J.G., Fritzler M.J. Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun. Rev. 2012, 11:642-645.
7. Ochs R.L., Muro Y., Si Y., Ge H., Chan E.K., Tan E.M. Autoantibodies to DFS 70kd/transcription coactivator p75 in atopic dermatitis and other conditions. J. Allergy Clin. Immunol. 2000, 105:1211-1220.
8. Watanabe K., Muro Y., Sugiura K., Tomita Y. IgE and IgG(4) autoantibodies against DFS70/LEDGF in atopic dermatitis. Autoimmunity 2011, 44:511-519.
9. Ochs R.L., Mahler M., Basu A., Rios-Colon L., Sanchez T.W., Andrade L.E., et al. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin. Exp. Med. 2015, (in press).
10. Miyara M., Albesa R., Charuel J.L., El Amri M., Fritzler M.J., Ghillani-Dalbin P., et al. Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort. Clin. Dev. Immunol. 2013, 2013:703759.
11. Mahler M., Parker T., Peebles C.L., Andrade L.E., Swart A., Carbone Y., et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J. Rheumatol. 2012, 39:2104-2110.
12. Watanabe A., Kodera M., Sugiura K., Usuda T., Tan E.M., Takasaki Y., et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004, 50:892-900.
13. Debyser Z., Christ F., De Rijck J., Gijsbers R. Host factors for retroviral integration site selection. Trends Biochem. Sci. 2015, 40:108-116.
14. Llano M., Morrison J., Poeschla E.M. Virological and cellular roles of the transcriptional coactivator LEDGF/p75. Curr. Top. Microbiol. Immunol. 2009, 339:125-146.
15. Basu A., Rojas H., Banerjee H., Cabrera I.B., Perez K.Y., De León M., et al. Expression of the stress response oncoprotein LEDGF/p75 in human cancer: a study of 21 tumor types. PLoS One 2012, 7:e30132.
16. Mediavilla-Varela M., Pacheco F.J., Almaguel F., Perez J., Sahakian E., Daniels T.R., et al. Docetaxel-induced PCa cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol. Cancer 2009, 8:68.
17. Huang T.S., Myklebust L.M., Kjarland E., Gjertsen B.T., Pendino F., Bruserud O., et al. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Mol. Cancer 2007, 6:31.
18. Daugaard M., Kirkegaard-Sorensen T., Ostenfeld M.S., Aaboe M., Hoyer-Hansen M., Orntoft T.F., et al. Lens epithelium-derived growth factor is an Hsp70-2 regulated guardian of lysosomal stability in human cancer. Cancer Res. 2007, 67:2559-2567.
19. Yokoyama A., Cleary M.L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008, 14:36-46.
20. Méreau H., De Rijck J., Cermáková K., Kutz A., Juge S., Demeulemeester J., et al. Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75). Leukemia 2013, 27:1245-1253.
21. Sapoznik S., Cohen B., Tzuman Y., Meir G., Ben-Dor S., Harmelin A. Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C. Cancer Res. 2009, 69:9306-9314.
22. Leitz J., Reuschenbach M., Lohrey C., Honegger A., Accardi R., Tommasino M., et al. Oncogenic human papillomaviruses activate the tumor-associated lens epithelial-derived growth factor (LEDGF) gene. PLoS Pathog. 2014, 10:e1003957.
23. Bhargavan B., Fatma N., Chhunchha B., Singh V., Kubo E., Singh D.P. LEDGF gene silencing impairs the tumorigenicity of PCa DU145 cells by abating the expression of Hsp27 and activation of the Akt/ERK signaling pathway. Cell Death Dis. 2012, 3:e316.
24. Daugaard M., Baude A., Fugger K., Povlsen L.K., Beck H., Sørensen C.S., et al. LEDGF (p75) promotes DNA-end resection and homologous recombination. Nat. Struct. Mol. Biol. 2012, 19:803-810.
25. Ge H., Si Y., Roeder R.G. Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J. 1998, 17:6723-6729.
26. Singh D.P., Ohguro N., Chylack L.T., Shinohara T. Lens epithelium-derived growth factor: increased resistance to thermal and oxidative stresses. Invest. Ophthalmol. Vis. Sci. 1999, 40:1444-1451.
27. Sharma P., Singh D.P., Fatma L.T., Chylack L.T., Shinohara T. Activation of LEDGF gene by thermal- and oxidative-stresses. Biochem. Biophys. Res. Commun. 2000, 276:1320-1324.
28. Singh D.P., Fatma N., Kimura A., Chylack L.T., Shinohara T. LEDGF binds to heat shock and stress-related element to activate the expression of stress-related genes. Biochem. Biophys. Res. Commun. 2001, 283:943-955.
29. Fatma N., Singh D.P., Shinohara T., Chrylack L.T. Transcriptional regulation of the AOP2 gene, a thiol-specific antioxidant, by LEDGF to protect cells from oxidative stress. J. Biol. Chem. 2001, 276:48899-48907.
30. Shin J.H., Piao C.S., Lim C.M., Lee J.K. LEDGF binding to stress response element increases alphaB-crystallin expression in astrocytes with oxidative stress. Neurosci. Lett. 2008, 435:131-136.
31. Cohen B., Addadi Y., Sapoznik S., Meir G., Kalchenko V., Harmelin A., et al. Transcriptional regulation of vascular endothelial growth factor C by oxidative and thermal stress is mediated by lens epithelium-derived growth factor/p75. Neoplasia 2009, 11:921-933.
32. Takeichi T., Sugiura K., Muro Y., Ogawa Y., Akiyama M. LEDGF/DFS70 activates the MK2/IL6/STAT3 pathway in HaCaT. J. Dermatol. Sci. 2011, 63:203-205.
33. Basu A., Drame A., Muñoz R., Gijsbers R., Debyser Z., De Leon M., et al. Pathway specific gene expression profiling reveals oxidative stress genes potentially regulated by transcription co-activator LEDGF/p75 in PCa cells. Prostate 2012, 72:597-611.
34. Bartholomeeusen K., Christ F., Hendrix J., Rain J.C., Emiliani S., Benarous R., Debyser Z., Gijsbers R., De Rijck J. Lens epithelium-derived growth factor/p75 interacts with the transposase-derived DDE domain of PogZ. J. Biol. Chem. 2009, 284:11467-11477.
35. Maertens G.N., Cherepanov P., Engelman A. Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J. Cell Sci. 2006, 119:2563-2571.
36. Bartholomeeusen K., De Rijck J., Busschots K., Desender L., Gijsbers R., Emiliani S., et al. Differential interaction of HIV-1 integrase and JPO2 with the C terminus of LEDGF/p75. J. Mol. Biol. 2007, 372:407-421.
37. Hughes S., Jenkins V., Dar M.J., Engelman A., Cherepanov P. Transcription co-activator LEDGF interacts with the S-phase kinase Cdc7:ASK and stimulates its enzymatic activity. J. Biol. Chem. 2010, 285:541-554.
38. Leoh L.S., van Heertum B., De Rijck J., Filippova M., Rios-Colon L., Basu A., et al. The stress oncoprotein LEDGF/p75 interacts with the methyl CpG binding protein MeCP2 and influences its transcriptional activity. Mol. Cancer Res. 2012, 10:378-391.
39. Bizzaro N., Tonutti E., Visentini D., Alessio M.G., Platzgummer S., Morozzi G., et al. Antibodies to the lens and cornea in anti-DFS70-positive subjects. Ann. N. Y. Acad. Sci. 2007, 1107:174-183.
40. Bizzaro N., Tonutti E., Villalta D. Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEP-2 cells: not an easy task! Comment on the article by Mariz et al. Arthritis Rheum. 2011, 63:4036-4037.
41. Mariz H.A., Sato E.I., Barbosa S.H., Rodrigues S.H., Dellavance A., Andrade L.E. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011, 63:191-200.
42. Fritzler M.J. The antinuclear antibody test: last or lasting gasp?. Arthritis Rheum. 2011, 63:19-22.
43. Cheng T.L., Qiu Z. MeCP2: multifaceted roles in gene regulation and neural development. Neurosci. Bull. 2014, 30:601-609.
44. Gijsbers R., Ronen K., Vets S., Malani N., De Rijck J., McNeely M., et al. LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol. Ther. 2010, 18:552-560.
45. Goto N., Sugiura K., Ogawa Y., Watanabe A., Onouchi H., Tomita Y., et al. Anti-p80 coilin autoantibodies react with a conserved epitope and are associated with anti-DFS70/LEDGF autoantibodies. J. Autoimmun. 2006, 26:42-51.
46. Daniels T., Zhang J., Gutierrez I., Elliot M.L., Yamada B., Heeb M.J., et al. Antinuclear autoantibodies in PCa: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 2005, 62:14-26.
47. Ogawa Y., Sugiura K., Watanabe A., Kunimatsu M., Mishima M., Tomita Y., et al. Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain. J. Autoimmun. 2004, 23:221-231.
48. Muro Y., Sugiura K., Morita Y., Tomita Y. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus 2008, 17:171-176.
49. Fitch-Rogalsky C., Steber W., Mahler M., Lupton T., Martin L., Barr S.G., et al. Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One 2014, 9:e93812.
50. Fabris M., Zago S., Tosolini R., Melli P., Bizzaro N., Tonutti E. Anti-DFS70 antibodies: a useful biomarker in a pediatric case with suspected autoimmune disease. Pediatrics 2014, 134:e1706-e1708.
51. Cherepanov P., Devroe E., Silver P.A., Engelman A. Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J. Biol. Chem. 2004, 279:48883-48892.
52. Cherepanov P., Maertens G., Proost P., Devreese B., Van Beeumen J., Engelborghs Y., et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 2003, 278:372-381.
53. Llano M., Saenz D.T., Meehan A., Wongthida P., Peretz M., Walker W.H., et al. An essential role for LEDGF/p75 in HIV integration. Science 2006, 314:461-464.
54. Wu X., Daniels T., Molinaro C., Lilly M.B., Casiano C.A. Caspase cleavage of the nuclear autoantigen LEDGF/p75 abrogates its pro-survival function: implications for autoimmunity in atopic disorders. Cell Death Differ. 2002, 9:915-925.
55. Ullal A.J., Pisetsky D.S. The role of microparticles in the generation of immune complexes in murine lupus. Clin. Immunol. 2013, 146:1-9.
56. Tran T.H., Mattheolabakis G., Aldawsari H., Amiji M. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clin. Immunol. 2015, (in press).
57. Abeles A.M., Abeles M. The clinical utility of a positive antinuclear antibody test result. Am. J. Med. 2013, 126:342-348.
58. Chida N., Kobayashi I., Takezaki S., Ueki M., Yamazaki Y., Garelli S., et al. Disease specificity of anti-tryptophan hydroxylase-1 and anti-AIE-75 autoantibodies in APECED and IPEX syndrome. Clin. Immunol. 2015, 156:36-42.
59. Shen L., Suresh L., Lindemann M., Xuan J., Kowal P., Malyavantham K., Ambrus J.L. Novel autoantibodies in Sjogren's syndrome. Clin. Immunol. 2012, 145:251-255.
60. D'Angelo S., Mignone F., Deantonio C., Di Niro R., Bordoni R., Marzari R., et al. Profiling celiac disease antibody repertoire. Clin. Immunol. 2013, 148:99-109.
61. Dai L., Ren P., Liu M., Imai H., Tan E.M., Zhang J.Y. Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma. Clin. Immunol. 2014, 152:127-139.